ScreenerHero

KLRA Kailera Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · kailera.com
10.53USD-2.77%Mkt Cap: 1.37B $P/E: —

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.37B USD
Enterprise Value497.52M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-148.96M USD
Revenue/Share—
Last Price10.53 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.52
PEG—
EV/EBITDA-1.59
EV/Revenue—
P/S—
P/B1.26
EPS (TTM)-4.50
EPS (Forward)-4.30
52W Range
9.8504% of range28.23
52W High28.23 USD
52W Low9.850 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE41.79%
ROA-21.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-120.21M USD
CapEx (TTM)2.09M USD
FCF Margin—
FCF Yield—
Net Debt-906.52M USD
Net Debt/EBITDA2.90
Balance Sheet
Debt/Equity-0.03
Current Ratio11.11
Quick Ratio11.03
Book Value/Sh8.63 USD
Cash/Share7.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.40 USD
Upside (mean)+302.7%
Target Range30.00 USD – 57.00 USD
30.00+302.7% to mean57.00
# Analysts5
Ownership
Shares Out.129.64M
Float58.48M
Insiders8.91%
Institutions90.30%
Short Interest
Short Ratio7.1d
Short % Float4.60%
Short % Out.4.60%
Shares Short5.96M
Short (prev mo.)6.07M
Technical
SMA 5015.55 (-32.3%)
SMA 20018.94 (-44.4%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)1.20M
Avg Vol (10d)1.61M
Technical Indicators
RSI (14)30.8
MACD-1.4167
MACD Signal-1.4350
MACD Hist.+0.0183
BB Upper14.74 USD
BB Middle12.14 USD
BB Lower9.538 USD
BB Width42.83%
ATR (14)0.9948 USD
Vol Ratio (20d)0.78x